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Abstract
Purpose: To assess the efficacy and survival rate of the Trabectome-mediated ab interno
trabeculectomy combined with non-fenestrated Baerveldt glaucoma implant compared with
the Baerveldt glaucoma implant alone.
Method: In this retrospective comparative case series, 175 eyes undergoing primary
glaucoma surgery (Baerveldt–Trabectome [BT] group: 60 eyes and Baerveldt [B] group: 115
eyes) were included. Participants were identified using the procedural terminology codes.
Groups were then matched by Coarsened Exact Matching that resulted in the inclusion of
51 eyes in each group. The primary outcome measure was surgical success defined as 5
mmHg < intraocular pressure (IOP) ≤ 21 mmHg, and IOP reduction ≥ 20% from baseline,
and no need to reoperation for glaucoma. Secondary outcome measures were IOP, number
of glaucoma medications, and best-corrected visual acuity (BCVA).
Results: The cumulative probability of success at one year was 61% in the BT group and 50%
in the B group. IOP decreased from 23.5 ± 2.4 mmHg at baseline to 14.1 ± 2.7 mmHg at the
final follow-up in the BT group (P = 0.001). The corresponding values for the B group were
23.2 ± 2.0 mmHg and 13.9 ± 1.6 mmHg, respectively (P = 0.001). There was no significant
difference between the groups in terms of IOP at the final follow-up (P = 0.56). The number of
medications at baseline was 2.3 ± 0.3 in both groups. However, the BT group needed fewer
drops at all postoperative time intervals and used 1.1 ± 0.3 versus 2.0 ± 0.4 eye drops (group
B) at the final follow-up visit (P = 0.004). Eyes in B with phacoemulsification had a significantly
higher IOP on day 1 compared to B (23.2 ± 14.3 versus 17.9 ± 11.4, P = 0.041). During the one-
year follow-up, 7 (13.7%) patients in BT group and 18 (35.2%) in B group experienced hypotony
(P = 0.04). No dangerous hypotony or hypertension occurred in BT group. Themean BCVA at
baseline was 0.64 ± 0.85 logMAR and changed to 0.55 ± 0.75 logMAR in BT and B groups,
respectively (P = 0.663). The corresponding numbers for the final follow-up visit was 0.72 ±
1.07 and 0.63 ± 0.97 logMAR, respectively (P = 0.668).
Conclusion: We observed similar rates of success and IOP reduction using BT and
B techniques. BT group needed fewer glaucoma medications. Tube fenestration was
unnecessary in BT group resulting in less postoperative ocular hypotony and hypertension.
The results of our study indicate that additional trabectome procedure makes Baerveldt
glaucoma implant safer, easier to handle, and more predictable in the most vulnerable
patients with advanced glaucoma.
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INTRODUCTION
Trabeculectomy and large glaucoma drainage
devices (GDDs) are often chosen as primary
surgical interventions for refractory glaucoma
with a low target intraocular pressure (IOP).
Both allow to bypass the impaired conventional
outflow route and can achieve IOPs below that
of the episcleral veins. Trabeculectomy can be
associated with a high rate of failure and sight-
threatening complications.[1–4] Recent studies show
GDDs have the same or a higher success rate
than trabeculectomy in end-stage glaucoma but
a better safety profile.[1, 2, 5] As a result, GDDs are
increasingly used for refractory glaucoma or as the
primary procedure.
One of the most frequently implanted GDDs is
the Baerveldt implant (Advanced Medical Optics,
Santa Ana, California, USA). In contrast to the
Ahmed glaucoma implant (New World Medical
Inc, Rancho Cucamonga, California, USA), another
common device, the Baerveldt implant does not
have a flow restrictor and requires a ligature suture
that ties off the lumen to prevent hypotony[6] until
a capsule has formed around the implant after four
to six weeks.[7] The clinical definition of hypotony
is IOP low enough to result in vision loss caused,
for instance by corneal edema, astigmatism,
cystoid macular edema, or maculopathy.[8] Since
GDDs are often used in severe glaucoma with
advanced optic neuropathy, a high postoperative
IOP can be detrimental. To prevent this, many
surgeons use spatulated needles to create slit-
shaped fenestrations anterior to the ligature that
permit limited flow.[9–11] However, titrating this is
challenging and the effect can range from no flow
to frank hypotony.[10]
To address this problem and allow a
complete tube ligature without fenestration,
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we combined Baerveldt device implantations with
Trabectome-mediated ab interno trabeculectomy
(NeoMedix, Tustin, CA, USA). We hypothesized
that this would provide a moderate IOP reduction
until the ligature dissolves allowing safe flow into
a fully integrated Baerveldt implant. To achieve
a balanced comparison of Baerveldt implants
to Baerveldt implants with the same session
Trabectome surgery, we used Coarsened Exact
Matching (CEM), a computation-intense, modern
statistics method[12–15] that we applied to similar
questions before.[16, 17] Although a randomized
controlled trial remains the most effective tool
to reduce bias and patient selection, modern
statistical matching strategies can deliver a highly
balanced assessment of real-world patient data in
a retrospective analysis.
METHODS
This studywas approved by the Institutional Review
Board of the Human Subjects Research Committee
at the University of Pittsburgh. An informed
consent was not required for this retrospective
comparative case series. Our research adhered
to the tenets of the Declaration of Helsinki
and the regulations of the Health Insurance
Portability and Accountability Act. We identified
patients who underwent a primary Baerveldt
implantation (B) or primary Baerveldt implantation
with Trabectome surgery (BT) between 2008 and
2015 using the Current Procedural Terminology
(CPT) codes. All procedures were performed
by four glaucoma fellowship-trained surgeons.
Only patients older than 18 years with medically
uncontrolled IOP were included. The exclusion
criteria were neovascular glaucoma, uveitic
glaucoma, and history of prior ocular surgery
(except uncomplicated phacoemulsification).
We collected data including basic
demographics, type of glaucoma, preoperative
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IOP, number of glaucoma medications, best-
corrected visual acuity (BCVA), and type of surgery
and complications as well as the postoperative IOP,
number of medications, and BCVA.
The primary outcome measure was success
defined as 5 mmHg < IOP ≤ 21 mmHg and ≥ 20%
reduction of IOP from baseline at two consecutive
visits, no need for further glaucoma surgery, and
no loss of light perception. The secondary outcome
measures were IOP, BCVA, and the number of
medications. We defined hypotony as an IOP
low enough to cause vision loss from corneal
edema, astigmatism, cystoid macular edema, or
maculopathy.[8]
We measured the IOP with a Goldmann
applanation tonometer (GAT; Haag-Streit, Konig,
Switzerland) at the first day, 1 week, 4 ±1 weeks,
2–4 months, 5–7 months, 8–10 months, and 11–13
months. If more than one visit occurred during
these intervals, the visit closest to the months 6, 9,
or 12 was chosen.
Surgical Technique
In patients undergoing a Baerveldt implantation
associated with Trabectome surgery, the
Trabectome surgery was performed first. Briefly,
the patient’s head was tilted 30° away from
the surgeon and the microscope was tilted in the
opposite direction. A temporal 1.6 mm clear corneal
incision was created. The tip of the handpiece was
advanced into the anterior chamber and engaged
with the nasal trabecular meshwork (TM). Ablation
was initiated and advanced in anticlockwise
direction for 90° followed by another clockwise 90°
clockwise ablation at the original starting point.
The handpiece was withdrawn from the anterior
chamber, and the incision was hydrated to seal.
At the beginning of the Baerveldt implantation,
a fornix-based conjunctival flap was fashioned, and
the subtenon’s space was dissected until enough
space was created for the implant. The wings of
the 350 mm*mm Baerveldt implant were inserted
under the superior and lateral rectus muscles. The
plate was sutured to the sclera 10 mm posterior to
the limbus. The tube was cut with the bevel up to
allow an intracameral length of 2mm. The tubewas
ligated near the plate junctionwith a 7-0 polyglactin
910 suture (coated VICRYL, Ethicon, Somerville, NJ,
United States) and tested with BSS to confirmwater
tightness. The tube was then inserted into the
anterior chamber through a tunnel created with 23-
gauge needle and secured to the sclera with a 7-0
polyglactin loop stitch. In group B, but not in group
BT, the tube portion anterior to the ligature was
fenestrated with a single pass of the spatulated 7-0
needle. The tube was covered with a scleral patch
graft and the incision of conjunctiva and Tenon’s
layer was reapproximated. Most of the procedures
were performed by NAL except a few eyes in B
group that were operated by other surgeons.
At the conclusion of the surgery, an antibiotic
(moxifloxacin) and steroid (1% prednisolone
acetate) drops were applied. The antibiotic
was used four times per day for one week while
the steroid eye drops were used four times per
day for one month and then tapered by one drop
application each week.
Statistical Analysis
Demographical data were compared using the
Mann–Whitney U test and Chi-squared test for
continuous and categorical variables, respectively.
To avoid eliminating data with missing values,
Multiple Imputation in R was used (Core Team
R (2018) R: A Language and Environment for
Statistical Computing. R Foundation for Statistical
Computing, Vienna, Austria). Missing values of the
incomplete dataset were imputed m > 1 times,
thus creating m completed datasets. Second,
each of the m completed datasets were analyzed
independently. Finally, the results from each of
the m analysis were pooled into a final result.
Missing data like age, gender, and race were
imputed by generating five similar but non-
identical datasets. Groups were then matched by
Coarsened Exact Matching in R,[18] based on the
age, race, type of glaucoma, baseline IOP, and
number of preoperative glaucoma medications.
Univariate linear regression was used to
examine IOP reduction after surgery. Variables
statistically significant were included in the final
multivariate regression model. A P-value < 0.05
was considered statistically significant. Continuous
variables were expressed as mean ± SD. All
analyses were performed using R.
To compute the survival of subjects in
each group, Kaplan–Meier survival plots were
determined and compared using the log-rank
test. Statistical significance was set at P < 0.05.
Success was defined as the 5 mmHg < IOP ≤ 21
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mmHg, and IOP reduction ≥ 20% from baseline,
and no need to reoperation for glaucoma.
RESULTS
A total of 175 eyes undergoing primary glaucoma
surgery (60 eyes in the BT group and 115 eyes in
the B group) were enrolled in this study. Coarsened
Exact Matching resulted in 51 eyes in the BT group
matched to 51 eyes in the B group. All eyes had
completed one year of follow-up visits. Ina addition,
there was no significant difference between the
two groups regarding ethnicity, IOP, the number of
IOP-lowering medications, glaucoma type, and the
degree of VF loss (P > 0.05, Table 1).
The mean age of the study participants was
70.7 ± 11.1 years in the BT group and 67.2 ±
15.7 years in the B group (P = 0.116). Thirty
patients (59%) underwent phacoemulsification at
the time of glaucoma surgery in each group (P
=1.00). Primary open-angle glaucoma was the most
common diagnosis in both groups (65.0% and
56.5% in BT and B groups, respectively, P = 0.516).
Kaplan–Meier survival curves (Figure 1) showed
a mean duration of survival of 261.9 ± 21.9 days
in the BT group and 220.28 ± 17.5 in the B group
with no statistically significant difference between
the two groups (log rank = 2.53 P = 0.11). The
cumulative probability of qualified success at 3, 6,
and 12 months was 74%, 64%, and 61% respectively
in the BT group, and 66%, 52%, and 50% in the B
group.
In the subgroup analysis (Table 2), the mean
survival duration was 285.5 ± 25.8 days in the
BT group with phacoemulsification versus 225.8 ±
25.9 days in the B group with phacoemulsification
(log Rank = 2.17, P = 0.14). Results for glaucoma
surgery alone were 221± 37.2 days in the BT group
and 215.5 ± 23.6 days in the B group (log-rank
= 0.24, P = 0.624, Figure 1). Survival of BT with
phacoemulsification was not significantly different
from B with phacoemulsification (log-rank = 1.18, P
= 0.18). Similarly, there was no difference between
the B with phacoemulsification and B alone (log-
rank = 0.45, P = 0.50). In cases with concurrent
phacoemulsification, the success rate was 56% in
the BT and 52% in the B (P = 0.65), while in the
stand-alone glaucoma surgery, the success rate
was 61% in the BT and 51% in the B group (P = 0.31).
IOP was significantly decreased from 23.5 ± 2.4
mmHg at baseline to 14.1 ± 2.7 mmHg at final
follow-up in the BT group (P = 0.001, Figure 2). The
corresponding values for the B group were 23.2 ±
2.0 mmHg and 13.9 ± 1.6 mmHg, respectively (P
= 0.001). IOP varied more in the B group than in
the BT group during the early postoperative phase
with 6.3% of hypotony occurring in the BT versus
12.8% hypotony detecting in the B group. During
the one-year follow-up, 7 (13.7%) patients in the BT
group and 18 (35.2%) in the B group experienced
hypotony (P =0.04). Most of the hypotony episodes
were within the first month before suture opening.
There was no significant difference in IOP at the
final follow-up (P = 0.98). Eyes in the BT group
experienced a 9 ± 9.1 mmHg reduction in IOP
within one week after the surgery, compared to a
6 ± 12.3 mmHg IOP reduction in the B group (P =
0.09). On day one, IOP was comparable between
BT with and BT without phacoemulsification (20.3
± 11.1 mmHg versus 18.6 ± 12.7 mmHg, P =
0.56). The B group with phacoemulsification had a
significantly higher IOP on day 1 compared to the
B group without phacoemulsification (23.2 ± 14.3
mmHg versus 17.9 ± 11.4 mmHg, P = 0.041).
The baseline number of glaucoma medications
was 2.3 ± 0.3 in both groups (Figure 3). However,
the BT group needed significantly fewer drops at
all postoperative visits. At the final follow-up visit,
the number of glaucoma medications was 1.1 ± 0.3
drops in the BT and 2.0 ± 0.4 drops in the B (P =
0.003, Figure 3) groups.
The mean BCVA at the baseline was 0.64± 0.85
logMAR in the BT and 0.55 ± 0.75 logMAR in the
B (P = 0.663) groups. Corresponding numbers for
the final follow-up visit were 0.72 ± 1.07 and 0.63 ±
0.97 logMAR, respectively (P = 0.668).
The most common observation after the surgery
was hyphema in 30% of the eyes in the BT
group and 10% in the B group. Two eyes in
the BT group and three eyes in the B group
had shallow anterior chamber early after surgery
which resolved spontaneously. There was one
case of choroidal detachment in each group that
responded to conservative management.
DISCUSSION
Both BT and B techniques were effective in
reducing IOP. The IOP reduction of 31% at the
one-year follow-up was comparable to previous
reports.[19–21] However, the success rate in our
study was lower than the reported range in
512 JOURNAL OF OPHTHALMIC AND VISION RESEARCH VOLUME 15, ISSUE 4, OCTOBER-DECEMBER 2020
Combining Baerveldt Implant with Trabectome Negates Tube Fenestration; Esfandiari et al
Figure 1. (A) Kaplan–Meier survival plots for the BT and B groups with success defined as a final IOP of ≤ 21 mmHg and a 20%
reduction from baseline. Success rates of BT and B was similar in both groups. (B) survival plots of the BT and B for subgroup
analysis separated by (B) glaucoma surgery alone and (C) same-session phacoemulsification (lower right).
Figure 2. IOP in the B and BT groups. (A) IOP in the BT group was similar to the B group and trended toward a lower average
although tubes in the BT group were not fenestrated and trended toward a lower average IOP. (B) B and BT techniques as stand-
alone procedures. (C) B + phacoemulsification had a higher IOP on day 1 compared to subsequent IOPs. No such peak was seen
in the BT group. Mean ± 95% confidence interval.
the literature;[19–21] most likely the results of a
lower baseline IOP in our study as compared
to others. Although there was a trend toward
greater IOP reduction following BT technique
compared to B technique, a statistical significance
was not reached. However, the BT group required
significantly fewer medications postoperatively.
The number of glaucoma medications at one-
month postoperative visit was nearly three times
as high in the B group as surgeons struggled
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Figure 3. Preoperative and postoperative mean eyedrops for BT and B. Mean pre- and postoperative glaucoma medications for
subgroup analysis separated by glaucoma surgery only (B) and same session phacoemulsification (C). Represented as mean ±
95% confidence intervals.
to control the pressure in this phase of bleb
maturation.
Early complications of GDDs included hyphema,
a shallow or flat anterior chamber, tube-corneal
touch, corneal edema, and suprachoroidal
effusion.[6, 22] These complications are induced
by postoperative hypotony, more common in
the non-valved devices when the flow is not
restricted and when fenestration of the tube yields
excessive flow.[23] Complete ligation of the tube
can prevent postoperative hypotony,[24–27] but
high postoperative IOPs can be dangerous to
eyes with advanced glaucoma damage. Therefore,
tube ligation is often carried out in conjunction
with intraoperative longitudinally oriented, 2
mm fenestrations proximal to the ligation.[23]
Despite this, a postoperative hypertensive spike
may develop secondary to obstruction of the
fenestration, slit malfunction, or an insufficient
number of fenestrations.[9, 28] It is hard to titrate the
function of these fenestrations and they are hardly
reproducible. Intraoperative techniques such as
irrigating the tube after fenestration, cautery of
the bleeding episcleral vessels, and removing the
debris from the field of surgery are proposed to
improve the outcomes of fenestrations but it is still
unpredictable. Considering these limitations, we
added the same session Trabectome surgery
to prevent postoperative IOP spikes. This
procedure enhances the outflow by plasma-
mediated ablation of the TM and has a long track
record of efficacy and safety in various types of
glaucoma.[29–33]
Although Trabectome is a microsurgical
glaucoma surgery and is often used in earlier
glaucoma stages,[33] recent studies suggest it
can be effective in more severe glaucoma.[34]
While the success rate of Trabectome after
failed trabeculectomy and tube shunt procedure
supports its role in the management of severe
glaucoma,[35, 36] many eyes at that stage cannot
afford a surgical failure, that can occur if the
conventional drainage system downstream of the
TM also has a reduced flow capacity. The effect
of trabecular ablation is immediate and controls
IOP until absorbable ligation sutures dissolve,
and the Baerveldt implant begins to function. In
contrast to the temporary effect of fenestrations,
the IOP lowering of Trabectome persists after the
ligature suture is absorbed and has the additive
effect of reducing glaucoma medications. This
is not a small feat as nearly half of all glaucoma
patients experience local and systemic side effects
of topical drops.[37] Adverse medication effects
are an important reason for non-adherence[38]
and can also jeopardize the success of glaucoma
surgery.[39, 40] Conversely, reducing eye drops
measurably improves the quality of life.[41]
Since cataract and glaucoma frequently coexist,
many individuals in both groups underwent
both surgeries. IOP in BT group combined with
phacoemulsification was not significantly different
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from BT alone, reflecting our prior results that
phacoemulsification does not add to the IOP-
lowering effect when combined with Trabectome
surgery.[16, 17] Although phacoemulsification has
been advocated as providing a trabeculoplasty-
like, additional IOP reduction,[42] glaucomatous
TM is often unpredictable resulting in IOP spikes
at the time of stand-alone cataract surgery[43, 44]
as we have observed here as well on day 1 in
patients in group B with phacoemulsification. The
results of our study showed that this potentially
dangerous IOP spike could be prevented by the
same-session Trabectome surgery. Conversely, no
severe hypotony was seen in the BT group which
did not require tube fenestration.
Limitations of this study are inherent to the
retrospective nature compared to randomized
controlled trials. However, the CEM strategy
used here reduces imbalances without discarding
valid data. Although observational data is easy
to collect compared to randomized experiments,
how the treatments were assigned and other
aspects of data generation are often ambiguous
and difficult to control. CEM is a newer form of
automatic, nonparametric matching to control
the confounding influence of pretreatment
control variables by achieving an acceptable
balance between treated and control groups.[18]
Additionally, this study was conducted at a single
tertiary academic center, so the results cannot
easily be generalized to other practice facilities. It
should be noted that Trabectome surgery is a new
skill even for experienced surgeons and takes at
least 30 eyes to maximize the outflow,[44] therefore,
a complete 180° TM removal with Trabectome may
not always be achieved.
In summary, we found that Baerveldt
implants with same-session Trabectome surgery
resulted in a significantly decreased number of
glaucoma medications and avoided both severe
hypertension and hypotension, thereby negating
the need for tube fenestration.
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